Probucol

Medical uses

In Japan, it is approved for "hyperlipidemia (including familial hypercholesterolemia and xanthomas)".

Adverse effects

During both clinical trials and postmarketing surveillance, most adverse effects were limited to the digestive system and the skin. Those included diarrhea, abdominal pain, nausea, loss of appetite, rash, and itching. For each of these effect, the incidence was between 0.1% and 1% ("uncommon"). QT prolongation was noted as rare (

Possible serious adverse effects include ventricular arrhythmia (Torsades de pointes), syncope, gastrointestinal bleeding, peripheral neuritis, and rhabdomyolysis. The frequency of these are unknown.

Drug interactions

May reduce the blood concentration of cyclosporin (unknown mechanism). There exist reports of significantly declined HDL-C with clofibrate (unknown mechanism).

Risk of arrhythmia is elevated when used with other drugs that can cause arrhythmia, especially tricyclic antidepressants and phenothiazines. Potentiates the effect of diabetic medications and coumarin anticoagulants.

Mechanism of action

Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Specifically, this happens by changing the structure of LDL, among other effects. The LDL receptor is not involved: it works in rabbits and humans without a working LDL receptor (homozygous familial hypercholesterolemia). It also enhances the excretion of cholesterol into bile. It is able to lower LDL-C by 10-20%.

It is also a powerful antioxidant. At a low dose (insufficient to affect LDL-C or HDL-C levels), it prevents the oxidation of cholestrol in LDLs. This might slow the formation of foam cells, which form atherosclerotic plaques. It partially does this by increasing PON1 activity, thus increasing the antioxidant properties of HDL.

Probucol also lowers HDL-C (HDL cholesterol, i.e. the amount of cholesterol found in HDLs) by about 30%. This has historically caused its discontinuation from several Western countries. This has several causes:

1. It inhibits ABCA1-dependent cholesterol transport (but not SR-BI–mediated efflux), which moves cholesterol from cells such as macrophages into HDL.
2. It increases CETP activity by lowering the amount of ANGPTL3. This also causes an increase in preβ1-HDL (lipid-poor particles) and a decrease in HDL phospholipids.
3. It increases HDL absorption by the liver via SR-BI. Recall that one of the functions of HDL is reverse cholesterol transport (moving cholesterol from peripheral tissues into the liver). Inhibition of ABCA1 would be detrimental to the process, whereas enhancing CETP and SR-BI activities is beneficial for the transport function. Overall, probucol increases the capacity for reverse cholesterol transport, so the observed HDL-C reduction does not lead to a decrease in a patient's cholesterol-removing ability.

The adverse effect of QT prolongation is possibly due to inhibition of hERG trafficking.

Pharmacokinetics

Oral absorption is limited and erratic. Food increases absorption. With a single oral dose of 250 mg, tmax is at 18 hours post-ingestion. If taken daily, 3 to 4 months are required to reach steady-state concentrations.

The tissue distribution of probucol has been studied in rats, dogs, and monkeys using a 14C-labelled version of the drug. In rats, a single 100 mg/kg dose results in liver, adrenal glands, and brown fat concentrations at 3–10× plasma concentration and central nervous system, gonad, and eye concentrations at 1/7–1/20× plasma concentration. In rats, 21 days of continuous 100 mg/kg/d feeding results in accumulation in brown fat, adrenal glands, liver, and adipose tissue at 10–46× plasma concentration and central nervous system, gonad, and eye concentrations at 1–1/2× plasma concentration.

Research

Probucol has been found to have antioxidant and anti-inflammatory properties via several different mechanisms. These properties have led to research into the drug's potential capacity to treat sensorineural hearing loss related to oxidative stress, as well as formulations to improve the delivery of the drug into the ear.

After promising test results in mouse models, probucol is under study at Weston Brain Institute of McGill University as a possible aid in delaying the onset of Alzheimer's disease. The protocol for a future Australian Phase II study was published in 2022.

Novel packaging methods have been tried to optimize the pharmacokinetic properties of probucol – the goal is usually to produce a more stable absorption profile and to reduce absorption by cardiac muscle cells. Some show promise in lab animals, but have not yet been tested in humans.

Analogues

A number of probucol analogues have been tested in animal models by researchers seeking to optimize aspects of probucol's action while reducing its side effects. Succinobucol, the succinate ester of probucol, failed to demonstrate a useful degree of efficacy in clinical trials targeting acute coronary syndrome. BO-653, another analogue, failed its phase II trial targeting atherosclerosis treatment and prevention of post-angioplasty restenosis.

Society and culture

In Japan, Probucol was available under both the Lorelco brand name, the Sinlestal brand name, and the generic "TOWA" brand. In January 2021, Towa Pharmaceutical Co., Ltd. announced that it would discontinue the sale of Probucol Tablets 250 mg "TOWA" due to various circumstances.

References

References

1. "中国药典".
2. Yamamoto A. (11 December 2008). "A Unique Antilipidemic Drug - Probucol". Journal of Atherosclerosis and Thrombosis.
3. (August 2015). "Did we abandon probucol too soon?". Current Opinion in Lipidology.
4. (November 2009). "Where are we with probucol: a new life for an old drug?". Atherosclerosis.
5. (March 2021). "Toward a broader view of mechanisms of drug cardiotoxicity". [[Cell Reports]].
6. (February 2021). "New Horizons for Probucol, an Old, Mysterious Drug". Journal of Atherosclerosis and Thrombosis.
7. "普罗布考片".
8. "ロレルコ錠250mg/ロレルコ細粒50% 添付文書 第15版".
9. (November 2011). "シンレスタール錠250mg/シンレスタール細粒50% 添付文書".
10. (22 November 2011). "Abstract 12669: Effect of Probucol on Antioxidant Properties of HDL in Patients with Heterozygous Familial Hypercholesterolemia". Circulation.
11. (28 October 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol..
12. (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis.
13. (1989). "Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer". Arteriosclerosis.
14. (July 2021). "A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology". [[Pharmaceutics (journal).
15. (May 2023). "Pharmaceutical characterization of probucol bile acid-lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies". [[Nanomedicine (Future Medicine journal).
16. (February 2022). "Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)". BMJ Open.
17. (January 2024). "The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases". Translational Neurodegeneration.
18. "Notice of Discontinuation of Probucol Tablets 250mg "TOWA"".